Q4 2025 revenue reached $83.3 million, representing a 9% year-over-year growth. Full Year 2025 revenue was $322.7 million, an increase of 14% year-over-year. The company reported a GAAP loss of $23.4 million, or ($0.76) per share, for Q4 2025. Non-GAAP income for Q4 2025 was $5.2 million, or $0.16 per share. For the full year 2025, GAAP loss was $60.5 million, or ($1.97) per share. Full year 2025 Non-GAAP income was $13.2 million, or $0.42 per share. Fulgent Genetics ended 2025 with $705.5 million in cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of approximately $106.3 million. The therapeutic development pipeline advanced, with FID-007 progressing through Phase 2 and FID-022 through Phase 1. For the full year 2026, the company expects revenue of approximately $350.0 million and a Non-GAAP loss of approximately ($1.45) per share. Expected cash, cash equivalents, restricted cash, and investments in marketable securities are approximately $685.0 million by December 31, 2026, assuming receipt of the $106 million tax refund, the Bako and StrataDx acquisition of $56 million, capital purchases of $12 million, and therapeutic development spend of $26 million.